Hopp til hovedinnhold

Humant papillomavirus (HPV)

Sist revidert:
Sist revidert av:


Definisjon:
Er en gruppe dobbelt-trådete DNA-virus som infiserer hud eller slimhinner hos mennesker. Kjent for å forårsake intraepiteliale lesjoner, oftest i cervix, og vorter
Forekomst:
Er den vanligste seksuelt overførbare infeksjonen med opptil 79% livstidsprevalens. Genitale vorter finnes hos ca. 1% av seksuelt aktive
Symptomer:
Sykdom kan manifestere seg som genitale vorter eller som lav- eller høygradige intraepiteliale lesjoner, hyppigst på livmorhalsen
Funn:
Eventuelt genitale vorter
Diagnostikk:
Kan påvises ved HPV-DNA eller HPV-mRNA test i væskebasert prøve fra livmorhals/skjede
Behandling:
Vaksine mot HPV-typene 16 og 18 er innført i barnevaksinasjonsprogrammet
  1. Juckett G, Hartman-Adams H. Human papillomavirus: Clinical manifestations and prevention. Am Fam Physician 2010; 82: 1209-14. American Family Physician  
  2. Muñoz N, Bosch FX, de Sanjos S, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27. New England Journal of Medicine  
  3. Naucler P, Ryd W, Tärnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97. New England Journal of Medicine  
  4. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007; 196 (10): 1447. pmid:18008222 PubMed  
  5. GLOBOCAN 2008. Cervical cancer incidence and mortality worldwide in 2008: summary. Accessed August 31, 2010.
  6. Skare GB, Bjørge T, Tropé A. Masseundersøkelsen mot livmorhalskreft. Kreftregisteret: Oslo; 2016. Hentet 14.01.2019. www.kreftregisteret.no  
  7. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907. PubMed  
  8. Mejlhede N, Bonde J, Fomsgaard A. High frequency of multiple HPV types in cervical specimens from Danish women. APMIS 2009; 117: 108-14. PubMed  
  9. Rodríguez AC, Schiffman M, Herrero R, et al. Rapid Clearance of Human Papillomavirus and Implications for Clinical Focus on Persistent Infections. J Natl Cancer Inst 2008; 100 (7): 513-7. doi:10.1093/jnci/djn044
  10. Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195: 1582-9. pmid:17471427 PubMed  
  11. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. The Lancet Infectious Diseases 2009; 9 (6): 347-56. doi:10.1016/S1473-3099(09)70108-2 DOI  
  12. Cox JT, Moriarty AT, Castle PE. Commentary on: statement on HPV DNA test utilization. J Low Genit Tract Dis 2009; 13: 131-4. PubMed  
  13. Abramowitz L1, Jacquard AC, Jaroud F, et al. Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer 2011; 129 (2): 433-9. doi:10.1002/ijc.25671 DOI  
  14. Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125: 362-6. PubMed  
  15. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191: 731-8. PubMed  
  16. Burchell AN, Winer RL, de Sanjos S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24(suppl 3): S3/52-S3/61.
  17. Kreimer AR, Campbell CM, Lin HY, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013. doi:10.1016/S0140-6736(13)60809-0 DOI  
  18. Hernandez BY, McDuffie K, Zhu X, et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev 2005; 14: 2550-6. PubMed  
  19. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354: 2645-54. New England Journal of Medicine  
  20. Wen LM, Estcourt CS, Simpson JM, Mindel A. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect 1999; 75: 312-6. PubMed  
  21. Jensen KE, Thomsen LT, Schmiedel S. Chlamydia trachomatis and risk of cervical intraepithelial neoplasia grade 3 or worse in women with persistent human papillomavirus infection: a cohort study. Sex Transm Infect 2014. doi:10.1136/sextrans-2013-051431 DOI  
  22. Kaderli R, Schnüriger B, Brügger LE. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis 2014. pmid:24935346 PubMed  
  23. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 1274-80. PubMed  
  24. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004; 190: 37-45. PubMed  
  25. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24: 35-41. doi:10.1016/j.vaccine.2006.06.015 DOI  
  26. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005; 32(suppl 1): S82-S90.
  27. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006; 208: 152-64. PubMed  
  28. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26(suppl 10): K1-K16. PMID: 18847553 PubMed  
  29. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncology 2009; 10: 321-2. doi:10.1016/S1470-2045(09)70096-8 DOI  
  30. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009; 113: 18-25. PubMed  
  31. Sun V, Chang L, Rutherford GW. Human papillomavirus (HPV) vaccine for individuals with HIV infection (Protocol). Cochrane Database of Syst Rev 2013. doi:10.1002/14651858.CD010493 DOI  
  32. Nygård M, Andreassen T, Berland J, et al. 2013. HPV-test i primærscreening mot livmorhalskreft. Kontrollert implementering og evaluering av forbedret helsetjeneste. Oslo, Helsedirektoratet.
  33. Pathak N, Dodds J, Zamora J, et al. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ. 2014 Sep 16;349:g5264. doi: 10.1136/bmj.g5264 DOI  
  34. Leinonen MK, Schee K, Jonassen CM et al. Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. J Clin Virol 2018; 99: 22-30. pmid:29289814 PubMed  
  35. Arbyn M, Smith SB, Temin S et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ 2018. doi:https://doi.org/10.1136/bmj.k4823
  36. Polman NJ, Ebisch RMF, Heideman DAM et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol 2019; 20: 229-38. pmid:30658933 PubMed  
  37. Giuliano AR, Lee J-H, Fulp W, et al. Incidence and clearance of genital human papillomavirus. Lancet, published online March 1 2011.
  38. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002; 35: 1127-34. PubMed  
  39. Cranston RD, Hart SD, Gornbein JA, Hirschowitz SL, Cortina G, Moe AA. The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men. Int J STD AIDS 2007; 18: 77-80. PubMed  
  40. Folkehelseinstituttet. HPV-vaksine (Humant papillomavirus) - veileder for helsepersonell. Vaksinasjonsveilederen, sist oppdatert 17.06.2020. www.fhi.no  
  41. Kavanagh K, Pollock KG, Cuschieri K et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017; 17: 1293-302. pmid:28965955 PubMed  
  42. Paavonen J, Naud P, Salmerón J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: epub301. pmid:19586656 PubMed  
  43. WHO position paper: Human papillomavirus vaccines - May 2017. Wkly Epidemiol Rec 2017;92(19):241 PubMed  
  44. Fairley CK, Hockin JS, Gurrin LC, et al. Rapid decline in presentations for genital warts after the implementation of a national quadrivalent human papillomavirus vaccination program for young women. Sex Transm Infect 2009; : PMID: 19837728 PubMed  
  45. Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 2016. doi: 10.1542/peds.2015-1968 DOI  
  46. de Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56. pmid:20952254 PubMed  
  47. Villa LL, Costa RLR, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8. PubMed  
  48. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. Obstet Gynecol 2006; 107: 18-27. PubMed  
  49. Andreassen T, Vogt C. Screening for livmorhalskreft i endring. Tidsskrift for Den norske legeforening 2014; 11: 1122-3. doi:10.4045/tidsskr.14.0240 DOI  
  50. Kreftregisteret. Årsrapport for Masseundersøkelsen mot livmorhalskreft 2011
  • Ingard Løge, spesialist allmennmedisin, redaktør NEL

Tidligere fagmedarbeidere

  • Sveinung Sørbye, overlege, avdeling for klinisk patologi, Universitetssykehuset i Nord-Norge, Tromsø